The compound was called Luminase-R.
Lucan had been calling it that for three years in his private research notes -- not because the name had been formally designated anywhere, but because it was the name the mechanism deserved. Luminase: the light-producing element at the core of the Lumen biopressure cycle. R: restorative. Not just treating Lucent Rot. Reversing the tissue cascade. Giving back what the disease had taken.
He had been calling it Luminase-R since before he had proof it could exist.
On the morning of Day 128, the synthesis run produced a viable compound for the first time.
He ran the verification three times. Not because he doubted the first result, but because he had been wrong before, in the second year and the fourth year and the tenth year, and he had learned to hold results carefully until they had been confirmed from multiple angles. The third verification came back identical to the first two. The compound was viable. Not a partial result. Not a theoretical proof. A real, physical vial of stable Luminase-R sitting in the containment rack of his research wing.
He sat at the workstation for a long time without moving.
---
Mirelle noticed the silence.
She had been in the analysis room working on the relay documentation when the synthesis run completed -- she knew the sound of the run cycle finishing, the specific harmonic of the lab equipment returning to standby. What she did not hear was the normal post-run sequence: Lucan writing in the research log, the workstation processing, the scratch of pen on paper.
Silence.
She knew his silence the way she knew the station's ventilation frequency -- by texture and duration. This silence had a different texture.
She knocked on the partition frame. He looked up.
She looked at the containment rack.
He watched her read the result on the screen behind the rack and she read it with the same focused compression she brought to everything important -- not slowly, not dramatically, but with the specific quality of someone who understood what they were looking at and was making sure they understood it correctly before responding.
"Viable," she said.
"Yes."
She came into the research wing. She stood at the containment rack and looked at the vial. She did not touch it. She looked at it the way she had looked at the specimen case in the Surface Room when she had first found it -- with the attention of someone finding something that was not supposed to be findable.
"How long?" she said.
"Sixteen years since I started the research. Three years at this station. Eight weeks since we shifted to the stage one mechanism." He paused. "Eleven minutes and forty-three seconds since the verification completed."
She looked at him. The corner of her mouth -- not quite a smile, the thing that lived next to one.
"You counted," she said.
"I count things."
She looked back at the vial. "What happens now?"
He walked her through it: compound stabilization, three weeks to make it transit-safe. Then to Bellhaven through the provisional relay. Then the research registry review, the trial design, the enrollment process. Anwen could be in the first treatment cohort in six months.
"Six months," she said.
"If the timeline holds. These things move at the speed of institutional review."
She was quiet for a moment. Then: "Send word to Anwen tonight. Don't wait for the stabilization."
He had been planning to wait. He had told himself it was responsible -- not raise her expectations before the compound was confirmed transit-safe. He looked at Mirelle saying *don't wait* and understood what she was telling him: Anwen had been waiting for sixteen years too.
"All right," he said.
---
The celebration, such as it was, happened at the kitchen table over dinner.
Mirelle made the meal -- she had been doing this more often in the weeks since the transit route was finished, and he had stopped noting it as a change in pattern because it had become the pattern. He set the table. They ate.
"Tell me what the treatment looks like," she said. "If the trial works. What Anwen's life looks like."
He thought about it. "Stage II reversal is documented in the literature -- not from Luminase-R, from earlier partial compounds that showed mechanism proof. If the full reversal holds, she recovers near-normal tissue function within four to six months of treatment completion. She would be monitored for recurrence, but the cascade model suggests the reversal is durable."
"She goes home," Mirelle said.
"She goes home."
Mirelle looked at her plate. "She told me she wants to see the hydroponic trees flower. They flower every eighteen months. She has been waiting for the current cycle."
He looked at her. Mirelle had been corresponding with Anwen for months -- he knew this, it was visible in the relay logs, in the letters that came and went through Bren's network. He did not always know what they wrote to each other. He had not asked. But from the specific quality of how Mirelle said *she told me* -- not *she wrote* but *she told me* -- he understood that Anwen and Mirelle had built something he was not fully privy to, and that this was correct.
"She'll see them," he said.
Mirelle looked up. "You don't know that."
"No. But the compound is viable. We have six months. I'm choosing to say she'll see them."
Mirelle looked at him. He held the look.
"All right," she said. "She'll see them."
---
He wrote to Anwen after dinner.
He did not show the letter to Mirelle -- some things between him and Anwen were private, as some things between Mirelle and Anwen were private, and he had come to understand this structure as healthy rather than exclusionary. Three people who had arrived at trust from different directions, holding different pieces of the same story.
He told Anwen about the viable compound. He told her about the timeline. He told her he had made a choice tonight to say she would see the trees flower, which was not a clinical statement but which was what he had and he was offering it.
At the end of the letter he wrote: *Mirelle says to tell you the transit hour came through the greenhouse panels today at a particularly good angle. She described it this morning. I have the notes if you want them.*
He sealed the letter. He put it in the relay envelope.
He went to the Surface Room, where the notebook was on the shelf. He sat in the window chair -- her chair, technically, though she never said so and he had started sitting in it when she was not there because it faced the monitoring display correctly for late-evening reading. He opened the notebook to the synthesis record section.
He turned pages. He reached the current section. He wrote the day's entry:
*Luminase-R viable. Day 128. Compound confirmed, three independent verifications. Stabilization begins tomorrow. Estimated transit to Bellhaven: three weeks. Estimated first treatment: six months.*
He looked at this. It was an accurate record. It was also not the full record of the day.
He turned to the surface section and wrote:
*No surface run today. The transit hour: she said the angle was good. I did not go up. I was in the lab. I am writing this down because it is what today was -- a day I was in the lab and the transit hour was good and Luminase-R is real and she said don't wait.*
He closed the notebook. He went back to the research wing.
He opened the scale-up model -- the full theoretical analysis he had been building in parallel with the synthesis work, the framework for production beyond single-subject dosage. He had been building this in the background for weeks, which was normal research practice. He opened it now with the specific intent of confirming what he had been avoiding confirming.
He read to page three. He read to page four.
He closed the model.
He sat in the research wing for a long time.
---
The scale-up model was a theoretical framework he had been building since the original synthesis research began.
Any pathologist working on a novel compound built scale-up models in parallel -- it was standard research practice, the preparation for the question that followed proof of concept: if this works for one person, how does it work for a thousand? The model was not the research. It was the preparation for what the research would need to become.
He had been building this model for three years. He had been refining it as the synthesis pathway clarified and the mechanism analysis deepened. In the past eight weeks, with the stage one intervention confirmed and the restorative property established, the model had become substantially more detailed.
Page four was where the detail became specific.
He read it again.
The compound required a biological precursor that could not be manufactured or synthesized from standard sources. The precursor was present in the Vesperin cascade -- specifically in the marrow-level cellular expression of the cascade mechanism, which was different from the blood-level expression they had been working with. The difference mattered: blood-level samples were renewable, could be taken over time, could be provided voluntarily with full consent. Marrow-level extraction was a different order of procedure.
He ran the model's calculation against the scale requirements.
For single-subject treatment: blood-level samples were sufficient. The three sessions they had run, the contact work, the controlled compounds -- all of this was enough to treat one person.
For seed culture -- the biological foundation for production at scale -- the model was unambiguous. He had run this calculation four times from different angles over the past three days. Each calculation returned the same result.
He sat with page four for a long time.
He thought about what he would do with this.
The honest answer was: he did not know yet. He needed more information. He needed to confirm the model from an independent angle. He needed to look for alternative pathways -- the model might have gaps, might have assumptions that didn't hold, might be missing something he had not considered. He had been known to miss things. The steric configuration error in week four was proof that his models were not infallible.
He would look for the alternative pathway first. He would approach this the way he approached everything: with systematic analysis, with the acknowledgment that he might be wrong, with the commitment to following the evidence wherever it led.
And he would not tell Mirelle until he knew what the evidence was.
He told himself this was because she should not have to worry about a theoretical model that might contain errors. He told himself he was protecting the integrity of his own research process -- that stating a result before it was confirmed would be irresponsible. He told himself there was a reasonable scientific case for the sequence of: confirm the alternative first, then discuss.
He did not examine whether he was telling himself the truth.
He closed the model. He opened the compound stabilization protocol, which was the next day's work and which was real and necessary and good. He worked on the stabilization protocol until midnight. He went to bed.
In the morning the station was the same station: the tea, the surface notebook, the analysis room, the maps, the thirty-eight centimeters. She came into the kitchen and said: *"Synthesis update?"* He said: *"Stabilization begins today. On track for three-week transit window."* She nodded. She went to the analysis room.
He took his tea to the research wing.
He did not open the scale-up model.
He worked on the stabilization protocol, which was the right work for the day, which was proceeding correctly, which was good. He had sixteen years of working alone and he was working alone with this and it was the same.
He told himself it was the same.
---
Three days later, he read page four for the fifth time.
He had been looking for the error in the model. He had been systematic about it: checking assumptions, running alternative calculations, looking for the gap in his reasoning that would change the conclusion. He had found two minor errors -- one in the baseline yield calculation, one in the cascade timing estimate. He had corrected both. The corrected model returned the same result as the original.
He had then gone back to the Heliogen records -- the fragments he had reconstructed, the pieces that had survived the deletion. Looking for any record of an alternative pathway that Heliogen had tried and abandoned. There was a section in the Year 3 documentation that referenced a different extraction approach. He had spent two days reconstructing the fragments. The alternative approach had been abandoned because it produced insufficient yield. The notes did not say why the yield was insufficient. He had tried to reconstruct the chemistry from the remaining fragments.
The chemistry confirmed the original model.
He had been wrong twice about model errors in his research history. Both times, the error had been in an assumption he had made in the first week of the model's construction. He had checked every first-week assumption. None of them were wrong.
He closed the model on the fifth reading.
He was not going to find an error because the model did not contain one. This was not a result he could change by looking at it from a different angle.
He was going to need to find an alternative pathway -- a different synthesis route, a different biological precursor, a different mechanism entirely. This was the research work of months, possibly a year. He did not have a year on Anwen's timeline.
He sat with all of this in the research wing at ten-thirty in the evening with the station quiet around him and the compound stabilization proceeding correctly and Mirelle asleep in the room forty meters down the corridor.
He thought about what she had said when they had established the conditions of the arrangement: *no hidden results. Everything you find, I know at the same time.*
He thought about the word he had written in the notebook.
He thought about page four.
He opened the scale-up model. He created a new encrypted folder in the research file system. He moved the model into it.
Then he opened the stabilization protocol and worked until midnight.
---
Anwen's reply came through the relay four days after he sent word.
The letter was two pages. The handwriting was looser than usual, the specific quality he had learned to recognize as Anwen writing quickly because she had too much to say to slow down. She wrote about the compound and about the timeline and about what six months meant to her, which she described in her characteristic way: *not abstractly, not in statistics, but as the specific list of things I have been waiting to do.* Seeing the trees flower was on the list. Also: eating a meal outside the facility, even if outside meant the courtyard. Meeting Mirelle in person. Reading the full collection of the book series she had not let herself start because starting a long series felt like a commitment she was not certain she could make.
She wrote: *You said she'll see the trees flower and I want to believe you. I am going to start the book series.*
He read this at the kitchen counter in the morning. He read it twice. He put it down.
Mirelle came in. She read his face the way she read everything -- efficiently, accurately, without requiring confirmation. She picked up the letter. She read it. She set it down carefully.
She did not say anything for a moment. Then: *"She's starting the book series."*
*"Yes."*
*"That's significant."*
*"I know."*
She poured her tea. She picked up the letter again and read the second page. She set it back down on the counter and went to the analysis room without saying anything else, which was not avoidance -- it was the specific quality of someone who had received something large and needed to take it somewhere private to hold it correctly.
He understood this. He went to the research wing.
He did not open the encrypted folder.
He worked on the stabilization protocol and thought about the book series and about six months and about the specific sequence of things that needed to be true for Anwen to start reading a long book series and believe she would finish it.
He thought: this is what it is for. All sixteen years. This is what it was for.
He thought: I need to find the alternative pathway.
He thought: I will find it.
He opened the research files and went back to work.
He would find it. He was certain of this the way he was certain of the compound, the way he had been certain of the stage one mechanism before the testing confirmed it. He would find it because the alternative was not acceptable and because he was good at finding what he was looking for when he was willing to look long enough.
He was very good at looking. He had been looking for sixteen years. He could look a little longer.
He told himself this at the research wing in the amber workstation light while the stabilization protocol ran its cycle and Mirelle was in the analysis room thirty meters away working on the relay documentation.
He told himself this and he believed it.
He did not open the encrypted folder. He worked on what was in front of him and he believed the thing he was telling himself and he did not yet examine whether he was telling himself the truth about that either.
The work was good. He had always been good at work. He went home to it now, the same way he always had, and let the day proceed.
You've reached the end of this chapter
The compound was called Luminase-R.
Lucan had been calling it that for three years in his private research notes -- not because the name had been formally designated anywhere, but because it was the name the mechanism deserved. Luminase: the light-producing element at the core of the Lumen biopressure cycle. R: restorative. Not just treating Lucent Rot. Reversing the tissue cascade. Giving back what the disease had taken.
He had been calling it Luminase-R since before he had proof it could exist.
On the morning of Day 128, the synthesis run produced a viable compound for the first time.
He ran the verification three times. Not because he doubted the first result, but because he had been wrong before, in the second year and the fourth year and the tenth year, and he had learned to hold results carefully until they had been confirmed from multiple angles. The third verification came back identical to the first two. The compound was viable. Not a partial result. Not a theoretical proof. A real, physical vial of stable Luminase-R sitting in the containment rack of his research wing.
He sat at the workstation for a long time without moving.
---
Mirelle noticed the silence.
She had been in the analysis room working on the relay documentation when the synthesis run completed -- she knew the sound of the run cycle finishing, the specific harmonic of the lab equipment returning to standby. What she did not hear was the normal post-run sequence: Lucan writing in the research log, the workstation processing, the scratch of pen on paper.
Silence.
She knew his silence the way she knew the station's ventilation frequency -- by texture and duration. This silence had a different texture.
She knocked on the partition frame. He looked up.
She looked at the containment rack.
He watched her read the result on the screen behind the rack and she read it with the same focused compression she brought to everything important -- not slowly, not dramatically, but with the specific quality of someone who understood what they were looking at and was making sure they understood it correctly before responding.
"Viable," she said.
"Yes."
She came into the research wing. She stood at the containment rack and looked at the vial. She did not touch it. She looked at it the way she had looked at the specimen case in the Surface Room when she had first found it -- with the attention of someone finding something that was not supposed to be findable.
"How long?" she said.
"Sixteen years since I started the research. Three years at this station. Eight weeks since we shifted to the stage one mechanism." He paused. "Eleven minutes and forty-three seconds since the verification completed."
She looked at him. The corner of her mouth -- not quite a smile, the thing that lived next to one.
"You counted," she said.
"I count things."
She looked back at the vial. "What happens now?"
He walked her through it: compound stabilization, three weeks to make it transit-safe. Then to Bellhaven through the provisional relay. Then the research registry review, the trial design, the enrollment process. Anwen could be in the first treatment cohort in six months.
"Six months," she said.
"If the timeline holds. These things move at the speed of institutional review."
She was quiet for a moment. Then: "Send word to Anwen tonight. Don't wait for the stabilization."
He had been planning to wait. He had told himself it was responsible -- not raise her expectations before the compound was confirmed transit-safe. He looked at Mirelle saying *don't wait* and understood what she was telling him: Anwen had been waiting for sixteen years too.
"All right," he said.
---
The celebration, such as it was, happened at the kitchen table over dinner.
Mirelle made the meal -- she had been doing this more often in the weeks since the transit route was finished, and he had stopped noting it as a change in pattern because it had become the pattern. He set the table. They ate.
"Tell me what the treatment looks like," she said. "If the trial works. What Anwen's life looks like."
He thought about it. "Stage II reversal is documented in the literature -- not from Luminase-R, from earlier partial compounds that showed mechanism proof. If the full reversal holds, she recovers near-normal tissue function within four to six months of treatment completion. She would be monitored for recurrence, but the cascade model suggests the reversal is durable."
"She goes home," Mirelle said.
"She goes home."
Mirelle looked at her plate. "She told me she wants to see the hydroponic trees flower. They flower every eighteen months. She has been waiting for the current cycle."
He looked at her. Mirelle had been corresponding with Anwen for months -- he knew this, it was visible in the relay logs, in the letters that came and went through Bren's network. He did not always know what they wrote to each other. He had not asked. But from the specific quality of how Mirelle said *she told me* -- not *she wrote* but *she told me* -- he understood that Anwen and Mirelle had built something he was not fully privy to, and that this was correct.
"She'll see them," he said.
Mirelle looked up. "You don't know that."
"No. But the compound is viable. We have six months. I'm choosing to say she'll see them."
Mirelle looked at him. He held the look.
"All right," she said. "She'll see them."
---
He wrote to Anwen after dinner.
He did not show the letter to Mirelle -- some things between him and Anwen were private, as some things between Mirelle and Anwen were private, and he had come to understand this structure as healthy rather than exclusionary. Three people who had arrived at trust from different directions, holding different pieces of the same story.
He told Anwen about the viable compound. He told her about the timeline. He told her he had made a choice tonight to say she would see the trees flower, which was not a clinical statement but which was what he had and he was offering it.
At the end of the letter he wrote: *Mirelle says to tell you the transit hour came through the greenhouse panels today at a particularly good angle. She described it this morning. I have the notes if you want them.*
He sealed the letter. He put it in the relay envelope.
He went to the Surface Room, where the notebook was on the shelf. He sat in the window chair -- her chair, technically, though she never said so and he had started sitting in it when she was not there because it faced the monitoring display correctly for late-evening reading. He opened the notebook to the synthesis record section.
He turned pages. He reached the current section. He wrote the day's entry:
*Luminase-R viable. Day 128. Compound confirmed, three independent verifications. Stabilization begins tomorrow. Estimated transit to Bellhaven: three weeks. Estimated first treatment: six months.*
He looked at this. It was an accurate record. It was also not the full record of the day.
He turned to the surface section and wrote:
*No surface run today. The transit hour: she said the angle was good. I did not go up. I was in the lab. I am writing this down because it is what today was -- a day I was in the lab and the transit hour was good and Luminase-R is real and she said don't wait.*
He closed the notebook. He went back to the research wing.
He opened the scale-up model -- the full theoretical analysis he had been building in parallel with the synthesis work, the framework for production beyond single-subject dosage. He had been building this in the background for weeks, which was normal research practice. He opened it now with the specific intent of confirming what he had been avoiding confirming.
He read to page three. He read to page four.
He closed the model.
He sat in the research wing for a long time.
---
The scale-up model was a theoretical framework he had been building since the original synthesis research began.
Any pathologist working on a novel compound built scale-up models in parallel -- it was standard research practice, the preparation for the question that followed proof of concept: if this works for one person, how does it work for a thousand? The model was not the research. It was the preparation for what the research would need to become.
He had been building this model for three years. He had been refining it as the synthesis pathway clarified and the mechanism analysis deepened. In the past eight weeks, with the stage one intervention confirmed and the restorative property established, the model had become substantially more detailed.
Page four was where the detail became specific.
He read it again.
The compound required a biological precursor that could not be manufactured or synthesized from standard sources. The precursor was present in the Vesperin cascade -- specifically in the marrow-level cellular expression of the cascade mechanism, which was different from the blood-level expression they had been working with. The difference mattered: blood-level samples were renewable, could be taken over time, could be provided voluntarily with full consent. Marrow-level extraction was a different order of procedure.
He ran the model's calculation against the scale requirements.
For single-subject treatment: blood-level samples were sufficient. The three sessions they had run, the contact work, the controlled compounds -- all of this was enough to treat one person.
For seed culture -- the biological foundation for production at scale -- the model was unambiguous. He had run this calculation four times from different angles over the past three days. Each calculation returned the same result.
He sat with page four for a long time.
He thought about what he would do with this.
The honest answer was: he did not know yet. He needed more information. He needed to confirm the model from an independent angle. He needed to look for alternative pathways -- the model might have gaps, might have assumptions that didn't hold, might be missing something he had not considered. He had been known to miss things. The steric configuration error in week four was proof that his models were not infallible.
He would look for the alternative pathway first. He would approach this the way he approached everything: with systematic analysis, with the acknowledgment that he might be wrong, with the commitment to following the evidence wherever it led.
And he would not tell Mirelle until he knew what the evidence was.
He told himself this was because she should not have to worry about a theoretical model that might contain errors. He told himself he was protecting the integrity of his own research process -- that stating a result before it was confirmed would be irresponsible. He told himself there was a reasonable scientific case for the sequence of: confirm the alternative first, then discuss.
He did not examine whether he was telling himself the truth.
He closed the model. He opened the compound stabilization protocol, which was the next day's work and which was real and necessary and good. He worked on the stabilization protocol until midnight. He went to bed.
In the morning the station was the same station: the tea, the surface notebook, the analysis room, the maps, the thirty-eight centimeters. She came into the kitchen and said: *"Synthesis update?"* He said: *"Stabilization begins today. On track for three-week transit window."* She nodded. She went to the analysis room.
He took his tea to the research wing.
He did not open the scale-up model.
He worked on the stabilization protocol, which was the right work for the day, which was proceeding correctly, which was good. He had sixteen years of working alone and he was working alone with this and it was the same.
He told himself it was the same.
---
Three days later, he read page four for the fifth time.
He had been looking for the error in the model. He had been systematic about it: checking assumptions, running alternative calculations, looking for the gap in his reasoning that would change the conclusion. He had found two minor errors -- one in the baseline yield calculation, one in the cascade timing estimate. He had corrected both. The corrected model returned the same result as the original.
He had then gone back to the Heliogen records -- the fragments he had reconstructed, the pieces that had survived the deletion. Looking for any record of an alternative pathway that Heliogen had tried and abandoned. There was a section in the Year 3 documentation that referenced a different extraction approach. He had spent two days reconstructing the fragments. The alternative approach had been abandoned because it produced insufficient yield. The notes did not say why the yield was insufficient. He had tried to reconstruct the chemistry from the remaining fragments.
The chemistry confirmed the original model.
He had been wrong twice about model errors in his research history. Both times, the error had been in an assumption he had made in the first week of the model's construction. He had checked every first-week assumption. None of them were wrong.
He closed the model on the fifth reading.
He was not going to find an error because the model did not contain one. This was not a result he could change by looking at it from a different angle.
He was going to need to find an alternative pathway -- a different synthesis route, a different biological precursor, a different mechanism entirely. This was the research work of months, possibly a year. He did not have a year on Anwen's timeline.
He sat with all of this in the research wing at ten-thirty in the evening with the station quiet around him and the compound stabilization proceeding correctly and Mirelle asleep in the room forty meters down the corridor.
He thought about what she had said when they had established the conditions of the arrangement: *no hidden results. Everything you find, I know at the same time.*
He thought about the word he had written in the notebook.
He thought about page four.
He opened the scale-up model. He created a new encrypted folder in the research file system. He moved the model into it.
Then he opened the stabilization protocol and worked until midnight.
---
Anwen's reply came through the relay four days after he sent word.
The letter was two pages. The handwriting was looser than usual, the specific quality he had learned to recognize as Anwen writing quickly because she had too much to say to slow down. She wrote about the compound and about the timeline and about what six months meant to her, which she described in her characteristic way: *not abstractly, not in statistics, but as the specific list of things I have been waiting to do.* Seeing the trees flower was on the list. Also: eating a meal outside the facility, even if outside meant the courtyard. Meeting Mirelle in person. Reading the full collection of the book series she had not let herself start because starting a long series felt like a commitment she was not certain she could make.
She wrote: *You said she'll see the trees flower and I want to believe you. I am going to start the book series.*
He read this at the kitchen counter in the morning. He read it twice. He put it down.
Mirelle came in. She read his face the way she read everything -- efficiently, accurately, without requiring confirmation. She picked up the letter. She read it. She set it down carefully.
She did not say anything for a moment. Then: *"She's starting the book series."*
*"Yes."*
*"That's significant."*
*"I know."*
She poured her tea. She picked up the letter again and read the second page. She set it back down on the counter and went to the analysis room without saying anything else, which was not avoidance -- it was the specific quality of someone who had received something large and needed to take it somewhere private to hold it correctly.
He understood this. He went to the research wing.
He did not open the encrypted folder.
He worked on the stabilization protocol and thought about the book series and about six months and about the specific sequence of things that needed to be true for Anwen to start reading a long book series and believe she would finish it.
He thought: this is what it is for. All sixteen years. This is what it was for.
He thought: I need to find the alternative pathway.
He thought: I will find it.
He opened the research files and went back to work.
He would find it. He was certain of this the way he was certain of the compound, the way he had been certain of the stage one mechanism before the testing confirmed it. He would find it because the alternative was not acceptable and because he was good at finding what he was looking for when he was willing to look long enough.
He was very good at looking. He had been looking for sixteen years. He could look a little longer.
He told himself this at the research wing in the amber workstation light while the stabilization protocol ran its cycle and Mirelle was in the analysis room thirty meters away working on the relay documentation.
He told himself this and he believed it.
He did not open the encrypted folder. He worked on what was in front of him and he believed the thing he was telling himself and he did not yet examine whether he was telling himself the truth about that either.
The work was good. He had always been good at work. He went home to it now, the same way he always had, and let the day proceed.
You've reached the end of this chapter